ArticleCell biology and toxicology2026
Endothelial progenitor cell derived extracellular vesicles promotes wound healing in diabetic mice via activating mobilization and neovascularization.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular Vesicle Therapies for Diabetic Skin Lesions: Mechanisms, Engineering, and Clinical Translation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetic patients face delayed wound healing due to angiogenesis dysfunction. This study aims to investigate the function of endothelial progenitor cell (EPC)-derived extracellular vesicles (EVs) in wound healing of diabetic mice, providing a theoretical basis for treating difficult-to-heal diabetic wounds. The full-thickness skin wound model was used as an animal model. After treatment with EPC-EVs, wound healing and histopathological structures were evaluated. Peripheral blood was collected to analyze circulating EPCs. In cell models, EV endocytosis, cell viability, angiogenic capacity, and cell migration were detected. miR-204-5p, lncRNA SNHG1, EIF4A3, and HDAC6 were detected. EVs derived from EPCs with miR-204-5p overexpression were extracted to investigate their effects on wound healing. The bindings between miR-204-5p and SNHG1, SNHG1 and EIF4A3, and EIF4A3 and HDAC6 mRNA were validated. EPC-EVs promoted wound healing in diabetic mice. EPC-EVs enhanced angiogenesis and migration in cell models. EPC-EVs with miR-204-5p overexpression exhibited better therapeutic effects. EPC-EVs delivered miR-204-5p into tissues/cells to lower SNHG1 expression. SNHG1 bound to EIF4A3 to increase HDAC6 expression. SNHG1/HDAC6 overexpression partly reversed the pro-angiogenic effects of EPC-EVs on diabetic wound healing and HG-impaired endothelial cells. In conclusion, EPC-EVs enhance EPC mobilization and angiogenesis to accelerate wound repair in diabetic mice via the miR-204-5p/SNHG1/HDAC6 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.